Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Proteon Inks Deal With Novartis

by Rick Mullin
March 16, 2009 | A version of this story appeared in Volume 87, Issue 11

Proteon Therapeutics has granted Novartis an exclusive option to acquire it after the successful completion of a Phase II clinical study of PRT-201, a treatment developed by the Waltham, Mass.-based biopharma company for patients with renal disease undergoing surgery for arteriovenous fistula creation. The deal with Novartis, including acquisition payment and potential milestone payments, could be worth as much as $550 million. Proteon also completed a $38 million equity financing round led by MPM Capital. PRT-201 is currently in preliminary Phase IIa trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.